Fig. 2

Treatment arm selection of patients enrolled in CTP at pilot sites. Flowchart illustrating eligible patients identified from the CARRA Registry, prospective patients included in the study, their treatment arms, follow-ups and results at 3 and 6 months. MTX, methotrexate; ADA, adalimumab; PO, oral; SC, subcutaneous